DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.

Stornetta, Alessia; Villalta, Peter W; Gossner, Frederike; Wilson, William R; Balbo, Silvia; Sturla, Shana J

Stornetta, Alessia; Villalta, Peter W; Gossner, Frederike; Wilson, William R; Balbo, Silvia; Sturla, Shana J.

Afiliação

Stornetta A; Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
Villalta PW; Masonic Cancer Center, University of Minnesota , 2231 Sixth Street Southeast, Minneapolis, Minnesota 55455, United States.
Gossner F; Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
Wilson WR; Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland , Auckland 92019, New Zealand.
Balbo S; Masonic Cancer Center, University of Minnesota , 2231 Sixth Street Southeast, Minneapolis, Minnesota 55455, United States.
Sturla SJ; Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.

Chem Res Toxicol ; 30(3): 830-839, 2017 03 20.

Article em En | MEDLINE | ID: mdl-28140568

Assuntos

Antineoplásicos/farmacologia; Adutos de DNA; Compostos de Mostarda Nitrogenada/farmacologia; Pró-Fármacos/farmacologia; Células HT29; Humanos; Técnicas In Vitro

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Adutos de DNA / Antineoplásicos / Compostos de Mostarda Nitrogenada Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google